Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Amgen, Inc.(NASDAQ:AMGN), Aetna Inc(NYSE:AET), Allergan, Inc.(NYSE:AGN), Amarin Corporation plc (ADR)(NASDAQ:AMRN)
Amgen, Inc.(NASDAQ:AMGN) managed to keep its fall at -0.28% on below-normal volume of 5.33 million shares. The stock settled at $116.85 after floating in a range of $116.07 to $117.61. Its latest price was $116.85, reaching market capitalization of $88.03 billion. Its 52-week range has been $81.40 to $117.15. Elan Corporation, plc operates as a biotechnology company in the United States, Ireland, and internationally.
Has AMGN Found The Bottom and Ready To Move Up? Find Out Here
Aetna Inc(NYSE:AET) traded down on a volume of 4.67 million, higher than its standard daily volume. Shares have dropped -0.17% to $64.73. Over the last twelve months, the stock has added 63.64% and faced a best price of $69.19. Aetna Inc. operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions.
Has AET Found The Bottom And Ready To Gain Momentum? Find Out Here
Allergan, Inc.(NYSE:AGN) settled +1.57% higher at $92.63 on above-normal volume of 4.66 million shares during the last trading day. The stock has its 12-month high at $116.45 and 52-week low price was $81.33. It traded in a range of $81.33 to $93.09 during the last trading day. Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological.
For How Long AGN Gloss will Attract Investors? Find out via this report
Amarin Corporation plc (ADR)(NASDAQ:AMRN) saw its price fall on below-normal volume, as 4.56 million shares changed hands when compared with its average daily volume of 4.85 million shares. The stock was down -2.95% to $6.41. It has fallen/gained over the last 12 months, dropping -52.06% and marked new low $5.12. Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids.
Will AMRN Get Buyers Even After The Recent Rally? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)